Document is current
Any future updates will be listed below
-
Authors
McDade, Eric
Llibre-Guerra, Jorge J.
Holtzman, David M.
Morris, John C.
Bateman, Randall J. https://orcid.org/0000-0002-7729-1702
-
Funding
Funding for this research was provided by:
National Institute on Aging (U01AG042791, R1AG046179, R01/R56 AG053267, U01AG059798)
- License Information
-
More Information
Article History
Received: 19 February 2021
Accepted: 10 June 2021
First Online: 21 July 2021
Declarations
:
: Not applicable.
: Not applicable.
: <b>Dr. McDade,</b> is the Associate Director of the DIAN-TU. He reports serving on a Data Safety Committee for Eli Lilly and Company and Alector; scientific consultant for Eisai and Eli Lilly and Company; institutional grant support from Eli Lilly and Company, F. Hoffmann-La Roche, Ltd. and Janssen. <b>Dr. Morris,</b> is the Friedman Distinguished Professor of Neurology, Director, Knight ADRC; Associate Director of DIAN and Founding Principal Investigator of DIAN. He is funded by NIH grants # P30 AG066444; P01AG003991; P01AG026276; U19 AG032438; and U19 AG024904. Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. <b>Dr. Holtzman,</b> is the Department Head of Neurology where the research is being conducted, is an inventor on patents for solanezumab, currently being tested in the DIAN-TU clinical trials. If solanezumab is approved as a treatment for Alzheimer’s disease or dominantly inherited Alzheimer’s disease, Washington University and Dr. Holtzman will receive part of the net sales of solanezumab from Eli Lilly and Company, which has licensed patents related to solanezumab from Washington University. <b>Dr. Bateman,</b> is the Director of the DIAN-TU and Principal Investigator of the DIAN-TU-001. He receives research support from the National Institute on Aging of the National Institutes of Health, DIAN-TU Trial Pharmaceutical Partners (Eli Lilly and Company, F. Hoffman-La Roche, Ltd., and Avid Radiopharmaceuticals), Alzheimer’s Association, GHR Foundation, Anonymous Organization, DIAN-TU Pharma Consortium (Active: Biogen, Eisai, Eli Lilly and Company, Janssen, F. Hoffmann-La Roche, Ltd./Genentech. Previous: AbbVie, Amgen, AstraZeneca, Elan, Forum, Mithridion, Novartis, Pfizer, Sanofi, United Neuroscience). He has been an invited speaker, advisory board member and consultant for F. Hoffman La Roche, Ltd., an invited speaker and consultant for AC Immune and Janssen and a consultant for Amgen and Eisai. <b>Dr. Llibre-Guerra</b>, reports no conflict of interest relevant to this manuscript.
